Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

Background Risks to mother and fetus following Ebola virus infection are very high. Evaluation of safety and immunogenicity of non-replicating Ebola vaccine candidates is a priority for use in pregnant women. This is the protocol for a randomized, open-label, single-center phase 3 clinical trial of...

Full description

Saved in:

Bibliographic Details
Published in:	Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 513 - 23
Main Authors:	Karita, Etienne, Nyombayire, Julien, Ingabire, Rosine, Mazzei, Amelia, Sharkey, Tyronza, Mukamuyango, Jeannine, Allen, Susan, Tichacek, Amanda, Parker, Rachel, Priddy, Frances, Sayinzoga, Felix, Nsanzimana, Sabin, Robinson, Cynthia, Katwere, Michael, Anumendem, Dickson, Leyssen, Maarten, Schaefer, Malinda, Wall, Kristin M.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 20.06.2022 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Adults Antibodies Biomedicine Clinical trials Drug therapy Ebola virus Epidemics Fatalities Fetuses Health Sciences Immunogenicity Medicine Medicine & Public Health Miscarriage Mothers Pregnancy Pregnant women Reactogenicity Risk assessment Statistics for Life Sciences Study Protocol Vaccine safety Vaccines Womens health Rwanda United States > US Ebola virus Pregnancy Vaccine safety Immunogenicity Reactogenicity
ISSN:	1745-6215, 1745-6215
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!